G+FLAS Life Sciences
Company Snapshot
Founded: 2014
Entity Type: Private
Region: Republic of Korea
Headquarter: Chungcheongbuk-do, Republic of Korea
Key Geographics: Republic of Korea, U.S.
Corporate Address: 123, Uiryodanji-gil, Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, Republic of Korea Tel: +82-043-236-2201 www.gflas.com
Company Overview
Founded in 2014, G+Flas Life Sciences Inc. develops CRISPR/Cas genome-editing technologies for a range of applications, including gene-therapy drugs, biopharmaceuticals and agriculture.
In October 2018, G+Flas launched CRISPR-Plus (proprietary MgCas12a) and CRISPR/Cas9 monoclonal antibody products.
G+Flas also markets technology tools for delivering gene-editing ribonucleoprotein constructs into plant protoplasts.
G+FLAS Life Sciences In News
Company's Business Segments
- Products : CRISPR Genome Editing, CRISPR PLUSTM Gene Editing Tools, Technology for Delivering Gene Editing Molecular Scissors into plant protoplasts
- Services : Non-GMO Plant Transformation, Plant-based 'trastuzumab' biosimilar antibody, Cas9 monoclonal antibody, Host plants with glycotechnology, Others
Applications/End User Industries
- Biotechnology
- Pharmaceuticals
- Healthcare
- Oncology
- Agriculture
- Academic and Research
- Life Sciences